Key Highlights
- Eli Lilly is purchasing Centessa Pharmaceuticals in an all-cash transaction at $38 per share, representing approximately $6.3 billion in value
- An additional contingent value right (CVR) worth about $9 per share could elevate the transaction to $7.8 billion total
- Shares of Centessa’s U.S.-traded stock soared 46% during premarket hours following the announcement
- The purchase centers on acquiring Centessa’s sleep-wake disorder drug candidates
- Separately, Lilly revealed a $2.75 billion partnership with Insilico Medicine focused on AI-driven drug development
Eli Lilly revealed Tuesday its intention to purchase Centessa Pharmaceuticals through a transaction worth approximately $6.3 billion. The pharmaceutical giant is offering $38 in cash for each share of the Frankfurt-based biotech company.
The agreement includes a non-transferrable contingent value right valued at about $9 per share. Should this CVR trigger payment, the acquisition’s total worth would climb to roughly $7.8 billion.
Shares of Centessa traded in the United States jumped 46% during premarket hours after the deal was made public. The significant price increase demonstrates the substantial premium Lilly is offering to secure Centessa’s sleep medicine assets.
Centessa Pharmaceuticals plc, CNTA
The transaction centers on treatments for sleep-wake disorders, representing a new therapeutic category for Lilly. Centessa possesses a focused development pipeline that Lilly believes holds strong commercial promise.
This acquisition represents Lilly’s second significant transaction announcement within two consecutive days. The previous day, Monday, the company unveiled a $2.75 billion collaboration with Insilico Medicine aimed at commercializing AI-discovered therapeutics worldwide.
The Insilico partnership, which leverages artificial intelligence for identifying drug candidates, demonstrates Lilly’s strategy of combining conventional pharmaceutical development with cutting-edge technology platforms.
Strategic Entry Into Sleep Disorders
The purchase of Centessa represents a deliberate strategic expansion into sleep-wake disorder therapeutics. This therapeutic area has garnered increasing interest from large pharmaceutical companies in recent years.
Centessa has been advancing orexin receptor agonists, a drug class that activates the brain’s mechanisms responsible for wakefulness. These compounds show considerable promise for addressing conditions including narcolepsy and excessive daytime sleepiness.
Lilly’s decision to offer a substantial premium indicates strong conviction in the clinical value of these pipeline assets. The CVR arrangement also links a portion of the payment to achieving specific future development goals.
AI Partnership Rounds Out Active Period
The Insilico collaboration announced Monday introduces another strategic element to Lilly’s recent business activity. Insilico employs artificial intelligence to generate novel drug candidates, a methodology that may significantly reduce early-stage development timelines.
Lilly stated it will license and advance therapeutics identified through Insilico’s computational platform. Complete financial details beyond the $2.75 billion total have not been publicly revealed.
Announcing two transactions of this magnitude within a 24-hour period is remarkable even for a pharmaceutical company with Lilly’s resources. LLY shares were trading approximately 1% higher Tuesday morning as market participants assessed both agreements.
Centessa’s Frankfurt-traded shares also experienced substantial gains following the news, as the cash offer significantly exceeded recent market prices.
